Nurx, a San Francisco-based online prescribing startup, announced on Aug. 15 the close of a $52 million Series C funding round.
The investment was led by Kleiner Perkins Digital Growth Fund and Union Square Ventures, with additional participation from Y Combinator startup accelerator, the Reproductive Health Investors Alliance and more. The funding will be used to grow its medical provider team, refine its online platform and expand its offerings to address more health concerns.
Nurx currently offers prescriptions for various forms of birth control and the HIV prevention medication PrEP, and recently began distributing at-home HPV and STI testing kits, with plans to expand this focus on reproductive health. "By focusing our efforts on health needs that often carry shame and stigma, we're excited to reach more people and provide them with more sensitive healthcare services they need and deserve," said CEO Varsha Rao.
The latest funding round brings Nurx's valuation to nearly $300 million, TechCrunch reports. News of the startup's continued growth comes just a few months after The New York Times published an exposé in which several former employees claimed Nurx had a history of blatantly violating state and federal laws pertaining to the sale and distribution of prescription medication. In response, Ms. Rao acknowledged and pledged to rectify the "mistakes" of the company's former leadership.
More articles on telehealth:
New Hampshire passes law to expand telemedicine services
Shriners Twin Cities, Boys Town Hospital partner on telehealth services
Dartmouth-Hitchcock unveils telemedicine ICU unit